Natera IPO
Natera is a genetic testing and diagnostics company that provides testing services across women's health, oncology, and organ transplantation. The company is known for its non-invasive prenatal testing (NIPT) and liquid biopsy technologies that analyze cell-free DNA in blood samples. Natera's tests help healthcare providers make informed decisions about pregnancy management, cancer treatment, and transplant monitoring.
What We Know
Natera went public in July 2015, trading on NASDAQ under the ticker symbol NTRA. The company's IPO raised approximately $52 million at $18 per share. Since going public, Natera has expanded its testing portfolio beyond women's health into oncology and transplant medicine, growing through both organic development and strategic acquisitions. As a public company, Natera has focused on advancing its liquid biopsy technology and expanding market adoption of its tests. The company has invested heavily in clinical studies to support the clinical utility of its tests and has worked to secure reimbursement coverage from payers. Natera has also expanded internationally and formed partnerships with healthcare systems and other companies.
Frequently Asked Questions
Has Natera had an IPO?
Yes, Natera has been a public company since July 2015. The company went public on NASDAQ under the ticker symbol NTRA.
When is the Natera IPO date?
Natera completed its IPO in July 2015, raising approximately $52 million at $18 per share. The company has been publicly traded for nearly a decade.
How can I buy Natera stock?
You can buy Natera stock through any brokerage account as it trades publicly on NASDAQ under the ticker symbol NTRA. The stock is available through standard online and traditional brokerage services.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts